
Research Article

Evaluation of a microRNA-based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava

Mischa J. Kotlyar^{1, †}, Markus Krebs^{2, †}, Maximilian Burger³, Hubert Kübler¹, Ralf Bargou², Susanne Kneitz⁴, Wolfgang Otto³, Johannes Breyer³, Daniel C. Verghe³, Burkhard Kneitz¹, Charis Kalogirou^{1, *}

¹ Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany

² Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany

³ Department of Urology, Caritas St. Josef and University of Regensburg Medical Center, 93053 Regensburg, Germany

⁴ Physiological Chemistry I, Biocenter, University of Würzburg, 97074 Würzburg, Germany

† These authors contributed equally to this work.

* Correspondence: kalogirou_c@ukw.de; Tel.: +49 931 201 32001

Abstract: (1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava (ccRCC^{IVC}) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed a microRNA(miR)-based risk classifier – containing miR-21, miR-126 and miR-221 expression – which significantly predicted cancer-specific survival (CSS) of ccRCC^{IVC} patients. (2) Methods: Examining a single-center cohort of tumor tissue from n = 56 patients with ccRCC^{IVC}, we measured expression levels of miR-21, miR-126 and miR-221 by qRT-PCR. Prognostic impact of clinicopathological parameters and miR expression were investigated via univariate and multivariate cox regression. Referring to the previously established risk classifier, we performed Kaplan Meier analyses for single miR expression levels and the combined risk classifier. Cut-off values and weights within the risk classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were significantly associated with lymphonodal status at time of surgery, development of metastasis during follow-up, and cancer-related death. In Kaplan Meier analyses, miR-21 and miR-126 significantly impacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified ccRCC^{IVC} according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated the miR-based risk classifier within an independent ccRCC^{IVC} cohort.

Keywords: kidney cancer; RCC; venous infiltration; biomarker; cancer-specific survival; miR; risk stratification

1. Introduction

In about 10% of all cases, clear cell renal cell carcinomas (ccRCC) extend into the inferior vena cava (ccRCC^{IVC}) [1–3]. While constituting a high-risk setting in general, there still is substantial clinical heterogeneity within the ccRCC^{IVC} subgroup – with reported 5-year survival rates ranging from 37% to 65% for non-metastasized patients treated with nephrectomy in combination with tumor thrombectomy [4–9]. Regarding this discrepancy, biomarkers are urgently needed to identify patients with a specifically high risk of cancer relapse [10,11]. Potentially, ccRCC^{IVC} patients may also benefit from adjuvant systemic therapy and an intensified follow-up.

MicroRNAs (miRs) as biomarker candidates are post-transcriptional regulators of gene expression in various cancer entities [12–14]. Regarding ccRCC, several studies demonstrated the prognostic impact of miR expression levels in tumor tissue [15–17]. Previously, Vergho et al. established a combined risk classifier for patients with ccRCC^{IVC} receiving nephrectomy and thrombectomy in curative intention [10]. Based on miR-21, miR-126 and miR-221 expression in tumor tissue, the risk classifier significantly stratified patients regarding cancer-specific survival (CSS) in a single-center cohort ($n = 37$) – with a 5-year CSS of 78% vs. 18% in the favorable compared to the unfavorable subgroup [10].

To further assess the miR-based risk classifier as a prognostic tool in ccRCC^{IVC} patients, we retrospectively evaluated it within an independent cohort ($n = 56$) from the Department of Urology, University of Regensburg (Regensburg, Germany). Cut-off values for miR expression levels as well as internal classifier weights were transferred from the previous pilot study [10], in order to test its transferability to independent study cohorts. Figure 1 illustrates the course of our study.




Figure 1. Course of the study – using a microRNA (miR)-based risk classifier established previously [10], we examined the prognostic impact of miR-21, miR-126, and miR-221 expression in an independent cohort of clear cell renal cell carcinoma samples with infiltration of the inferior vena cava (ccRCC^{IVC}; $n = 54$). To assess the transferability of the miR-based risk classifier, cut-off value and weights were identical to the previous study.

2. Materials and Methods

2.1. Tumor Tissue Samples and Patients

Paraffin-embedded primary ccRCC^{IVC} tumor-samples of 56 subjects who underwent radical surgery were aggregated by the Department of Urology, University of Regensburg, Germany (1997–2006). A uropathologist selected sample-regions with > 90% cancerous tissue. Follow-up data were collected by the Department of Urology, University of Regensburg (Regensburg, Germany). The study was approved by the local Ethics Committee (Regensburg: Nr. 08/108). Detailed characteristics of the study cohort are summarized in Table 1.

2.2. RNA Extraction and qRT-PCR

Using the RecoverAll™ Total Nucleic Acid Isolation Kit (Thermo Fisher Scientific, Waltham, MA), total RNA from paraffin-embedded samples was isolated according to the manufacturer's instructions. RNA concentration and 260/280 ratio were analyzed by Spark® 10M (TECAN, Männedorf, Switzerland). cDNA was synthesized from total RNA with stem-loop reverse transcription primers (TaqMan microRNA Assay protocol, Applied Biosystems, Birchwood, UK). TaqMan microRNA Assay kit was used to quantify miR expression according to manufacturer's protocols. Samples showing a standard deviation > 0.5 were excluded (all reactions performed in triplicates). Small nuclear RNA (RNU6B) expression was used for normalization of miRs relative expression values. Samples with expression levels of RNU6B > 30 Ct were excluded from further analyses. Relative miR expressions were calculated using the ΔCt -method ($\Delta\text{Ct sample} = \text{Ct miR of interest} - \text{Ct RNU6B}$). To calculate fold changes in miR expression between samples, we used the $2^{\Delta\Delta\text{Ct}}$ method (in this study, referred to as the $\Delta\Delta\text{Ct}$ method).

2.3 Statistics and computational analysis

A Jupyter Notebook environment (version 6.3.0) was used to perform all statistical analyses using Python version 3.8.8, LifeLines version 0.27.0 [18], Pandas version 1.2.4 [19], Matplotlib 3.3.4 [20], Scipy version 1.6.2 [21].

To analyze differences between miR expression levels, we used Student's t-test for normally distributed data with similar variance – otherwise, Mann-Whitney-U-Test was applied. Data distribution and variance were assessed via Shapiro Wilk and Levene test, respectively. A significance level of 0.05 was applied.

2.3.1 Validation of microRNA-based Risk Classifier

To evaluate the validity of the miR-based risk classifier – $(4.592 \times \Delta\text{Ct miR-21}) + (-3.892 \times \Delta\text{Ct miR-126}) + (-1.938 \times \Delta\text{Ct miR-221})$ – weights and cut-off values ($\geq 18.7 \Delta\text{Ct} =$ “unfavorable subgroup”, $< 18.7 \Delta\text{Ct} =$ “favorable subgroup”) were transferred from the pilot study [10] and applied in order to stratify the ccRCC^{IVC} study cohort from Regensburg and perform Kaplan-Meier analyses. Within the risk classifier formula, a negative factor indicates that higher expression levels correlate with longer survival, while a positive factor correlates with shorter survival. For further analysis, we transferred cut-off values for miR-21 (8.17 ΔCt), miR-126 (3.57 ΔCt) and miR-221 expression (1.84 ΔCt) to evaluate their predictive potential in the new cohort using the Kaplan-Meier survival analysis.

2.3.2 microRNA-based Risk Classifier Calculation

Referring to the pilot study by Vergo et al. [22], the risk classifier was calculated as follows:

1. Performing uni- and multivariate Cox regression analysis, Vergo et al. evaluated the impact of clinicopathological parameters and various miRs on CSS.

2. To select the best fitting Cox model, the relative goodness-of-fit was measured based on the Akaike information criterion. The combination of miR-21, -126 and -221 displayed the best prediction properties. 104-106
3. Finally, the miR-based risk classifier was calculated based on the publication by Lossos et al. [23]. Hereby, a factor attained from the Cox model's z-score was identified for miR-21, -126 and -221. In the next step, relative expression levels (ΔCt) of miRs were multiplied by these factors (weights) using the formula $(4.592 \times \Delta\text{Ct miR-21}) + (-3.892 \times \Delta\text{Ct miR-126}) + (-1.938 \times \Delta\text{Ct miR-221})$. Risk score cut-off (18.7 ΔCt) was determined by ROC. 107-111

3. Results 112

Table 1 summarizes the basic clinical and pathological characteristics of our study cohort. Detailed follow-up information was available for 54 of 56 patients suffering from ccRCC^{IVC} (96.4%). 113-114

Table 1. Clinical and pathological patient characteristics ($n = 56$). Detailed follow-up information was available for 54 patients. 115-116

Characteristics	
Median Follow-up	94 (1 – 190) months
Median Age	67 (41 – 89) years
Sex	
female	22 (39.3%)
male	34 (60.7%)
Tumor Stage: pT3b	56 (100%)
Fuhrman Grade	
G2	41 (73.2%)
G3	15 (26.8%)
Nodal Status	
N0	45 (80.4%)
N+	11 (19.6%)
Distant Metastasis during Follow-up	
M0	35 (62.5%)
M1	21 (37.5%)
Median Tumor Size	70 (18 – 225) mm
Overall survival	
yes	27 (48.2%)
no	29 (51.8%)
Cancer-related death	
yes	13 (23.2%)
no	43 (76.8%)

3.1. Association of miR-21, -126 and -221 Expression with Clinicopathological Characteristics

To investigate the impact of miR-21, -126 and -221 within our ccRCC^{IVC} cohort, we associated expression levels of miR-21, miR-126 and miR-221 to relevant clinical parameters. Figure 2 illustrates the results.

At time of surgery, 11 of 56 ccRCC^{IVC} patients (19.6%) were diagnosed with nodal metastasis. In cases with positive nodal status, a trend towards up-regulation of miR-21 ($p = 0.065$) and a significant down-regulation of miR-126 ($p < 0.01$) were observed. For miR-221, there was no statistically significant association to nodal status.

During the follow-up period, distant metastasis emerged in 21 of 56 ccRCC^{IVC} patients (37.5%). As shown in Figure 2b, we observed a significant up-regulation of miR-21 ($p < 0.01$) and down-regulation of miR-126 ($p < 0.001$) as well as a trend towards downregulation for miR-221 ($p = 0.06$) in ccRCC^{IVC} samples of patients with metastasized disease.

Of 56 patients with ccRCC^{IVC}, 13 (23.2%) died during the follow-up period due to cancer (cancer-related death, CRD). Regarding miR expression levels, we found a significant up-regulation of miR-21 ($p < 0.001$) and a down-regulation of miR-126 ($p < 0.01$) in CRD cases. Instead, miR-221 expression did not show a statistically significant association to CRD in this analysis ($p = 0.27$).




Figure 2. miR-21, -126 and -221 expression levels depending on lymphonodal status (a), distant metastases (b) and cancer-related death (CRD, c). Significant changes between subgroups were calculated using unpaired Student's t test (CRD: miR-221; nodal status: miR-21, -221; distant metastases: miR-21, -126) or Mann-Whitney-U test (CRD: miR-21, -126; nodal status: miR-126; distant metastases: miR-221). $p < 0.05$ *; $p < 0.01$ **; $p < 0.001$ ***.

3.2. Cox regression Analysis

Next, we performed a univariate Cox regression analysis to further assess the prognostic potential of miR-21, -126, and -221 expression levels as predictors of CRD. Detailed follow-up information was available for 54 of 56 cases with a median of 94 months.

As summarized in Table 2a, miR-21 and miR-126 significantly predicted the occurrence of CRD in our study cohort ($p = 0.003$, Hazard Ratio (HR) 3.79 for miR-21, $p = 0.00003$, HR 0.19 for miR-126). In contrast, miR-221 expression in tumor tissue did not display significant prognostic potential ($p = 0.22$). Regarding further clinical parameters, significant results were also observed for nodal involvement, metastatic status and Fuhrman grade.

Additionally, as shown in Table 2b, we performed a multivariate Cox regression to investigate if the miR candidates remain acting as relevant predictors of CRD within our ccRCC^{IVC} cohort in attendance of nodal involvement and Fuhrman grade. Also under this conditions miR-21 and miR-126 significantly predicted the occurrence of CRD ($p = 0.02$, HR 4.94 for miR-21, $p = 0.01$, HR 0.27 for miR-126). MiR-221 expression again did not meet statistical significance as predictor of CRD ($p = 0.12$) (Table 2 and Figure 3d). No significant results were observed for the clinical parameters nodal involvement ($p = 0.71$) and Fuhrman grade ($p = 0.13$).

Table 2. (a) Univariate Cox regression of ccRCC^{IVC} patients for miR expression levels and clinicopathological parameters, (b) multivariate Cox regression for miR expression levels as well as Nodal Status and Fuhrman Grade. 95% Confidence intervals (CI) shown for Hazard ratios (HR). p values were computed using the chi-squared test. $p < 0.05$ *; $p < 0.01$ **; $p < 0.001$ ***.

Parameters	Cancer-related death			
	Univariate analysis		(b) Multivariate analysis	
	HR (95% CI)	p value	HR (95% CI)	p value
miR-21	3.79 (1.55 – 9.26)	0.003**	4.94 (1.29 – 18.98)	0.02*
miR-126	0.19 (0.09 – 0.42)	0.00003***	0.27 (0.097 – 0.75)	0.01*
miR-221	0.74 (0.46 – 1.19)	0.22	0.64 (0.37 – 1.12)	0.12
Age	0.98 (0.92 – 1.03)	0.42		
Sex	2.10 (0.58 – 7.65)	0.26		
Tumor size	1.01 (1.00 – 1.03)	0.07		
Fuhrman Grade	3.79 (1.27 – 11.33)	0.02*	3.28 (0.70 – 15.32)	0.13
Nodal status	6.70 (2.09 – 21.47)	0.001**	1.34 (0.29 – 6.12)	0.71
Distant metastasis	∞	NA		

Abbreviation: CI, confidence interval; HR, hazard ratio; ∞ / NA: In case of distant metastasis as predictor of CRD, the coefficient was not estimable (positively infinite). HR and p values were therefore not shown.

To further understand and illustrate the prognostic impact of single miRNAs on CSS (based on previously fitted multivariate Cox regression model), we plotted survival curves according to isolated miR expression levels (Figure 3a-c). For miR-21, higher relative expression levels were associated with lower CSS (Figure 3a). In contrast, higher expression levels of miR-126 as well as miR-221 were associated with higher CSS (Figure 3b, c).




Figure 3. (a–c) Survival curves for varying miR expression levels of miR-21, -126, -221 (based on fitted multivariate Cox regression model), illustrating partial effects of single miRNAs on cancer-specific survival for present study cohort ($n = 54$). The baseline represents median relative expression for each miRNA (miR-21 = 8.34 Δ Ct, miR-126 = 4.0 Δ Ct, miR-221 = 1.3 Δ Ct). Blue line represents minimum and brown line the maximum relative expression of each miRNA in present study cohort. Other expression levels were chosen randomly (1.0 Δ Ct steps). (d) Forest plot representing log Hazard Ratios (HR) from multivariate Cox regression of miR-21, miR-126, miR-221, Fuhrman Grade (Fuhrman) and nodal status (N-Status) for cancer-related death (CRD). p values were computed using the chi-squared test.

3.3. Kaplan Meier Analyses for single miR expression and the Risk Classifier

To investigate the prognostic transferability of single miRNAs, survival analyses using the cut-offs from Vergho et al. [10] were performed. Both, miR-21 and miR-126 showed a strong predictive significance in the Kaplan-Meier survival analysis (Fig. 4a, b). However, differences regarding CSS of miR-221 high vs. low expressing tumor specimens (Fig. 4c) did not reach statistical significance ($p = 0.25$).

To validate the predictive potential of the risk classifier (Fig. 4d), the established cut-off level of $18.7 \Delta Ct$ ($\geq 18.7 \Delta Ct$ = unfavorable subgroup, $< 18.7 \Delta Ct$ = favorable subgroup) was used to stratify the validation cohort consisting of $n = 54$ ccRCC^{IVC} tissue samples. Out of 13 CRD cases, the classifier correctly identified 12 patients who suffered from CRD as members of the unfavorable subgroup (92.3%; $\geq 18.7 \Delta Ct$). Overall, a sensitivity of 92.3% (CI 95%: 62.1% – 99.6%) and a specificity of 61.0% (CI 95%: 44.5% – 75.4%) were reached. Difference in 5-years and 10-years CSS was 100% vs. 70% and 94% vs. 31% between the favorable and the unfavorable subgroup, respectively.




Figure 4. Kaplan Meier survival analysis for CSS for external independent ccRCC^{IVC} ($n = 54$) cohort from Regensburg stratified by miR-21 (a), miR-126 (b) and miR-221 (c) expression levels. (d) Combined miR-based risk classifier (miR-21, -126, -221) using identical cut-offs and weights from a previous publication [10]. p values from log-rank tests are shown within each plot.

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

4. Discussion

193

ccRCCs infiltrating the inferior vena cava represent a clinically relevant high-risk subgroup. Still, there is substantial clinical heterogeneity within this distinct subgroup – and biomarkers are needed to assess the individual risk of progression. In general, adjuvant therapy with tyrosine kinase inhibitors (TKI) or immune checkpoint blockers could be a promising therapeutic option after nephrectomy – especially for patients suffering from high-risk RCC. However, European kidney cancer guidelines currently do not contain strong recommendations towards adjuvant therapies due to the mixed outcome in clinical trials [24]. For the TKI sunitinib, one trial displayed improved disease-free survival (DFS) for patients – while showing no significant differences in overall survival (OS) [25]. Additionally, another phase 3 trial did not detect significant survival effects for adjuvant sunitinib or sorafenib in nonmetastatic high-risk renal cell carcinoma [26]. Due to the sobering TKI results, research efforts were mainly shifted towards immune checkpoint blockers. For the PD-1 (Programmed Cell Death Protein 1) inhibitor pembrolizumab, KEYNOTE-564 trial detected improved progression-free survival (PFS) in an adjuvant setting after nephrectomy [27].

4.1. Evaluating a miR-based Risk Classifier for RCC with Infiltration of the Vena Cava

207

To estimate the individual risk of patients suffering from ccRCC^{IVC}, members of our research group have established a risk classifier based on the tissue expression of miR-21, miR-126, and miR-221 [10]. Former cohort contained tumor tissue of $n = 37$ patients undergoing surgery at the University Hospital of Würzburg, Germany. In this study, we externally validated the prognostic potential of the miR-based risk classifier. Therefore, we examined an independent cohort of ccRCC^{IVC} from the University of Regensburg, Germany ($n = 56$). To test the transferability and usability of the classifier within an external tissue cohort, we applied identical cut-off values and weights as in the previous pilot study.

Regarding clinicopathological characteristics of our study cohort, low miR-126 expression was significantly associated with a positive lymphonodal status at time of surgery. Moreover, occurrence of metastases during follow-up was significantly associated with higher miR-21 and lower miR-126 levels. Tumor tissue from patients suffering from CRD was also characterized by a significant upregulation of miR-21 and a downregulation of miR-126. Within univariate cox regression, miR-21 and miR-126 showed prognostic significance regarding cancer-specific survival (CSS). Lower levels of miR-221 in tumor tissue and its association with CRD did not reach statistical significance. Beyond miR expression, Fuhrman grade, lymphonodal status and occurrence of metastasis emerged as prognostically relevant. Next, we added a multivariate Cox regression for the three miR candidates. Again, this study identified miR-21 and miR-126 expression to significantly impact CRD. Kaplan Meier analyses based on cut-off values determined previously by Vergho et al. [10] confirmed the significant influence of miR-21 as well as miR-126 expression levels on CSS. Finally, applying the miR-based classifier using identical cut-off values and weights split patients in two groups.

Of note, the classifier nearly stratified the study cohort in two halves – with $n = 26$ patients belonging to the favorable and $n = 28$ patients belonging to the unfavorable subgroup. Regarding the substantial difference in CSS between both groups, adjuvant therapies appear promising especially for the unfavorable subgroup of ccRCC^{IVC} patients.

4.2. Functional Roles of miR-21, miR-126, and miR-221 in Cancer

233

After confirming the prognostic potential of the miR classifier using the validation cohort from Regensburg, we were interested in previously reported functions of these miRs in RCC and other malignancies. For miR-21, several researchers demonstrated oncogenic effects in various cancers, including RCC [28,29]. Among the prominent miR-21 target genes are key players of apoptosis induction like PDCD4 (Programmed Cell Death 4) [30] and genes like PTEN (Phosphatase and Tensin Homolog) [28]. Latter is an established tumor suppressor gene best known for regulating PI3K/Akt signaling. In contrast to miR-21, miR-126 acts as a tumor suppressor in tumor tissue, e. g. by targeting

ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1) [31] and VEGFA (Vascular Endothelial Growth Factor A) [32]. For miR-221, oncogenic versus protective functions appear to depend on the underlying cancer entity, as researchers demonstrated both roles [33–35]. For RCC, a down-regulation of miR-221 appears well in line with previous publications. Specifically, miR-221 is reported to regulate KDR (Kinase Insert Domain Receptor) – also known as VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) – in ccRCC [36] and prostate cancer [37], thereby regulating the sensitivity towards sunitinib. In summary, among diverse tumorigenic functions of these miRs, all three candidates prominently influence angiogenesis-related pathways (so-called AngiomiRs) [38,39]. Given that not all ccRCCs depend on angiogenic signaling to the same degree [40], it is tempting to assume that the unfavorable subgroup identified by our risk classifier could benefit from adjuvant anti-angiogenic therapy.

4.3. Limitations and Future Directions

Our study has several limitations. Leaving aside the definite RCC subgroup investigated here, sample size of our study is relatively small. Moreover, we purposely did not adjust cut-off values and individual miR weights determined previously in order to check the transferability of the risk classifier to external tissue cohorts. More research – ideally in a prospective setting – could further validate the risk classifier in a clinical setup and elucidate whether sub-classification of ccRCC^{IVC} is able to identify patients most susceptible towards adjuvant therapy.

5. Conclusions

While RCC extending into the inferior vena cava represents a high-risk setting, there is still substantial clinical heterogeneity within this patient subgroup. Previously, Vergho et al. established a miR-based risk classifier – containing miR-21, miR-126 and miR-221 expression – which significantly predicted CSS for patients from this subgroup. To validate this classifier, we examined its impact on an external and independent patient cohort. Using identical cut-off values for single miRs and identical weights within the classifier, we confirmed a highly significant risk stratification within the new cohort. Patients with an unfavorable constellation according to the miR-based classifier could especially benefit from adjuvant therapy and continuous follow-up examinations.

Author Contributions: Conceptualization, M.Ko., M.Kr., B.K., D.V. and C.K.; methodology, M.Kr., B.K., D.V. and C.K.; software, M.Ko., S.K. and B.K.; validation, M.Kr., M.B., J.B., H.K., D.V., B.K. and C.K.; formal analysis, M.Ko., S.K. and C.K.; investigation, M.Ko., M.Kr., W.O., J.B., S.K., B.K. and C.K.; resources, J.B. and B.K.; data curation, M.Ko., B.K. and C.K.; writing—M.Kr., M.Ko., J.B., B.K. and C.K.; writing—review and editing, M.Ko., M.Kr., M.B., H.K., R.B., W.O., J.B., S.K., D.V., B.K. and C.K.; visualization, M.Ko. and M.Kr.; supervision, M.B., H.K., R.B., W.O., D.V., B.K. and C.K.; project administration, M.Kr., B.K. and C.K.; funding acquisition, M.B. and H.K.

Funding: Markus Krebs was funded by a personal grant from Else-Kröner-Foundation (Else Kröner Integrative Clinician Scientist College for Translational Immunology, University Hospital Würzburg, Germany).

Institutional Review Board Statement: All procedures performed in studies involving human participants comply with the ethical standards laid down in the latest declaration of Helsinki of the World Medical Association. The study was approved by the local Ethics Committees (Regensburg: Nr. 08/108, Würzburg: Nr. 136/08). All involved patients gave their written and informed consent for the publication of their anonymized cases.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All data produced in the present study are available upon reasonable request to the authors. 285
286

Conflicts of Interest: The authors declare no conflict of interest. 287

References 288

1. Ljungberg, B.; Stenling, R.; Osterdahl, B.; Farrelly, E.; Aberg, T.; Roos, G. Vein Invasion in Renal Cell Carcinoma: Impact on Metastatic Behavior and Survival. *Journal of Urology* **1995**, *154*, 1681–1684, doi:10.1016/S0022-5347(01)66749-1. 289
290
291
2. Hoehn, W.; Hermanek, P. Invasion of Veins in Renal Cell Carcinoma -Frequency, Correlation and Prognosis. *Eur Urol* **1983**, *9*, 276–280, doi:10.1159/000474103. 292
293
3. Novick, A.C.; Cosgrove, D.M. Surgical Approach for Removal of Renal Cell Carcinoma Extending into the Vena Cava and the Right Atrium. *Journal of Urology* **1980**, *123*, 947–950, doi:10.1016/S0022-5347(17)56207-2. 294
295
4. Haferkamp, A.; Bastian, P.J.; Jakobi, H.; Pritsch, M.; Pfitzenmaier, J.; Albers, P.; Hallscheidt, P.; Müller, S.C.; Hohenfellner, M. Renal Cell Carcinoma With Tumor Thrombus Extension Into the Vena Cava: Prospective Long-Term Followup. *Journal of Urology* **2007**, *177*, 1703–1708, doi:10.1016/j.juro.2007.01.039. 296
297
298
5. Blute, M.L.; Leibovich, B.C.; Lohse, C.M.; Chevillet, J.C.; Zincke, H. The Mayo Clinic Experience with Surgical Management, Complications and Outcome for Patients with Renal Cell Carcinoma and Venous Tumour Thrombus. *BJU Int* **2004**, *94*, 33–41, doi:10.1111/j.1464-410X.2004.04897.x. 299
300
301
6. Vergho, D.C.; Loeser, A.; Kocot, A.; Spahn, M.; Riedmiller, H. Tumor Thrombus of Inferior Vena Cava in Patients with Renal Cell Carcinoma – Clinical and Oncological Outcome of 50 Patients after Surgery. *BMC Res Notes* **2012**, *5*, 264, doi:10.1186/1756-0500-5-264. 302
303
304
7. Haddad, A.Q.; Wood, C.G.; Abel, E.J.; Krabbe, L.-M.; Darwish, O.M.; Thompson, R.H.; Heckman, J.E.; Merrill, M.M.; Gayed, B.A.; Sagalowsky, A.I.; et al. Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. *Journal of Urology* **2014**, *192*, 1050–1056, doi:10.1016/j.juro.2014.03.111. 305
306
307
308
8. Klatté, T.; Pantuck, A.J.; Riggs, S.B.; Kleid, M.D.; Shuch, B.; Zomorodian, N.; Kabbinavar, F.F.; Beldegrun, A.S. Prognostic Factors for Renal Cell Carcinoma With Tumor Thrombus Extension. *Journal of Urology* **2007**, *178*, 1189–1195, doi:10.1016/j.juro.2007.05.134. 309
310
311
9. Berczi, A.; Flasko, T.; Szerafin, T.; Thomas, B.; Bacso, Z.; Berczi, C. Surgical Management and Outcome of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. *Urol Int* **2017**, *99*, 267–271, doi:10.1159/000464108. 312
313
314
10. Vergho, D.C.; Kneitz, S.; Kalogirou, C.; Burger, M.; Krebs, M.; Rosenwald, A.; Spahn, M.; Löser, A.; Kocot, A.; Riedmiller, H.; et al. Impact of MiR-21, MiR-126 and MiR-221 as Prognostic Factors of Clear Cell Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava. *PLoS ONE* **2014**, *9*, e109877, doi:10.1371/journal.pone.0109877. 315
316
317
318
11. Spachmann, P.J.; Breyer, J.; Kalogirou, C.; Lausenmeyer, E.-M.; Weber, F.; Prohaska, S.; Denzinger, S.; Burger, M.; Kübler, H.; Otto, W.; et al. Impact of E-Cadherin and β -Catenin as Prognostic Factor in Renal Cell Carcinoma with Tumor Thrombus of the Vena Cava. *Urol Int* **2019**, *102*, 413–420, doi:10.1159/000497279. 319
320
321
12. Ambros, V. MicroRNAs. *Cell* **2001**, *107*, 823–826, doi:10.1016/S0092-8674(01)00616-X. 322
13. Esquela-Kerscher, A.; Slack, F.J. Oncomirs — MicroRNAs with a Role in Cancer. *Nat Rev Cancer* **2006**, *6*, 259–269, doi:10.1038/nrc1840. 323
324
14. Kong, Y.W.; Ferland-McCollough, D.; Jackson, T.J.; Bushell, M. MicroRNAs in Cancer Management. *The* 325

-
- Lancet Oncology* **2012**, *13*, e249–e258, doi:10.1016/S1470-2045(12)70073-6. 326
15. Zaman, M.S.; Shahryari, V.; Deng, G.; Thamminana, S.; Saini, S.; Majid, S.; Chang, I.; Hirata, H.; Ueno, 327
K.; Yamamura, S.; et al. Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival. *PLoS* 328
ONE **2012**, *7*, e31060, doi:10.1371/journal.pone.0031060. 329
16. Vergho, D.; Kneitz, S.; Rosenwald, A.; Scherer, C.; Spahn, M.; Burger, M.; Riedmiller, H.; Kneitz, B. 330
Combination of Expression Levels of MiR-21 and MiR-126 Is Associated with Cancer-Specific Survival in Clear- 331
Cell Renal Cell Carcinoma. *BMC Cancer* **2014**, *14*, 25, doi:10.1186/1471-2407-14-25. 332
17. Spadaccino, F.; Gigante, M.; Netti, G.S.; Rocchetti, M.T.; Franzin, R.; Gesualdo, L.; Castellano, G.; 333
Stallone, G.; Ranieri, E. The Ambivalent Role of MiRNAs in Carcinogenesis: Involvement in Renal Cell 334
Carcinoma and Their Clinical Applications. *Pharmaceuticals* **2021**, *14*, 322, doi:10.3390/ph14040322. 335
18. Davidson-Pilon, C. Lifelines: Survival Analysis in Python. *JOSS* **2019**, *4*, 1317, doi:10.21105/joss.01317. 336
19. McKinney, W. Data Structures for Statistical Computing in Python. *Proceedings of the 9th Python in* 337
Science Conference **2010**, 56–61, doi:10.25080/Majora-92bf1922-00a. 338
20. Hunter, J.D. Matplotlib: A 2D Graphics Environment. *Computing in Science & Engineering* **2007**, *9*, 90– 339
95, doi:10.1109/MCSE.2007.55. 340
21. SciPy 1.0 Contributors; Virtanen, P.; Gommers, R.; Oliphant, T.E.; Haberland, M.; Reddy, T.; Cournapeau, 341
D.; Burovski, E.; Peterson, P.; Weckesser, W.; et al. SciPy 1.0: Fundamental Algorithms for Scientific Computing 342
in Python. *Nat Methods* **2020**, *17*, 261–272, doi:10.1038/s41592-019-0686-2. 343
22. Vergho, D.C.; Kneitz, S.; Kalogirou, C.; Burger, M.; Krebs, M.; Rosenwald, A.; Spahn, M.; Löser, A.; Kocot, 344
A.; Riedmiller, H.; et al. Impact of MiR-21, MiR-126 and MiR-221 as Prognostic Factors of Clear Cell Renal Cell 345
Carcinoma with Tumor Thrombus of the Inferior Vena Cava. *PLoS One* **2014**, *9*, e109877, 346
doi:10.1371/journal.pone.0109877. 347
23. Lossos, I.S.; Czerwinski, D.K.; Alizadeh, A.A.; Wechsler, M.A.; Tibshirani, R.; Botstein, D.; Levy, R. 348
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. *N Engl J Med* 349
2004, *350*, 1828–1837, doi:10.1056/NEJMoa032520. 350
24. Bedke, J.; Albiges, L.; Capitanio, U.; Giles, R.H.; Hora, M.; Lam, T.B.; Ljungberg, B.; Marconi, L.; Klatter, 351
T.; Volpe, A.; et al. 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant 352
Pembrolizumab for Renal Cell Carcinoma. *European Urology* **2022**, *81*, 134–137, 353
doi:10.1016/j.eururo.2021.11.022. 354
25. Ravaud, A.; Motzer, R.J.; Pandha, H.S.; George, D.J.; Pantuck, A.J.; Patel, A.; Chang, Y.-H.; Escudier, 355
B.; Donskov, F.; Magheli, A.; et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. *N* 356
Engl J Med **2016**, *375*, 2246–2254, doi:10.1056/NEJMoa1611406. 357
26. Haas, N.B.; Manola, J.; Uzzo, R.G.; Flaherty, K.T.; Wood, C.G.; Kane, C.; Jewett, M.; Dutcher, J.P.; Atkins, 358
M.B.; Pins, M.; et al. Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma 359
(ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial. *Lancet* **2016**, *387*, 360
2008–2016, doi:10.1016/S0140-6736(16)00559-6. 361
27. Choueiri, T.K.; Tomczak, P.; Park, S.H.; Venugopal, B.; Ferguson, T.; Chang, Y.-H.; Hajek, J.; Symeonides, 362
S.N.; Lee, J.L.; Sarwar, N.; et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. *N Engl* 363
J Med **2021**, *385*, 683–694, doi:10.1056/NEJMoa2106391. 364
28. Kalogirou, C.; Schäfer, D.; Krebs, M.; Kurz, F.; Schneider, A.; Riedmiller, H.; Kneitz, B.; Vergho, D. 365
Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on MiR-21-Mediated *PTEN* Expression. 366
Urol Int **2016**, *96*, 106–115, doi:10.1159/000441011. 367

-
29. Bautista-Sánchez, D.; Arriaga-Canon, C.; Pedroza-Torres, A.; De La Rosa-Velázquez, I.A.; González-Barrios, R.; Contreras-Espinosa, L.; Montiel-Manríquez, R.; Castro-Hernández, C.; Fragoso-Ontiveros, V.; Álvarez-Gómez, R.M.; et al. The Promising Role of MiR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics. *Molecular Therapy - Nucleic Acids* **2020**, *20*, 409–420, doi:10.1016/j.omtn.2020.03.003. 368–371
30. Li, X.; Xin, S.; He, Z.; Che, X.; Wang, J.; Xiao, X.; Chen, J.; Song, X. MicroRNA-21 (MiR-21) Post-Transcriptionally Downregulates Tumor Suppressor PDCD4 and Promotes Cell Transformation, Proliferation, and Metastasis in Renal Cell Carcinoma. *Cell Physiol Biochem* **2014**, *33*, 1631–1642, doi:10.1159/000362946. 372–374
31. Zhang, G.-M.; Luo, L.; Ding, X.-M.; Dong, D.-H.; Li, B.; Ma, X.-C.; Sun, L.-J. MicroRNA-126 Inhibits Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Renal Cell Carcinoma. *Molecular Medicine Reports* **2016**, *13*, 5029–5036, doi:10.3892/mmr.2016.5160. 375–377
32. Sasahira, T.; Kurihara, M.; Bhawal, U.K.; Ueda, N.; Shimomoto, T.; Yamamoto, K.; Kirita, T.; Kuniyasu, H. Downregulation of MiR-126 Induces Angiogenesis and Lymphangiogenesis by Activation of VEGF-A in Oral Cancer. *Br J Cancer* **2012**, *107*, 700–706, doi:10.1038/bjc.2012.330. 378–380
33. Garofalo, M.; Quintavalle, C.; Romano, G.; M. Croce, C.; Condorelli, G. MiR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy. *CMM* **2012**, *12*, 27–33, doi:10.2174/156652412798376170. 381–382
34. Li, F.; Xu, J.-W.; Wang, L.; Liu, H.; Yan, Y.; Hu, S.-Y. MicroRNA-221-3p Is up-Regulated and Serves as a Potential Biomarker in Pancreatic Cancer. *Artificial Cells, Nanomedicine, and Biotechnology* **2018**, *46*, 482–487, doi:10.1080/21691401.2017.1315429. 383–385
35. Kneitz, B.; Krebs, M.; Kalogirou, C.; Schubert, M.; Joniau, S.; van Poppel, H.; Lerut, E.; Kneitz, S.; Scholz, C.J.; Ströbel, P.; et al. Survival in Patients with High-Risk Prostate Cancer Is Predicted by MiR-221, Which Regulates Proliferation, Apoptosis, and Invasion of Prostate Cancer Cells by Inhibiting IRF2 and SOCS3. *Cancer Res.* **2014**, *74*, 2591–2603, doi:10.1158/0008-5472.CAN-13-1606. 386–389
36. Khella, H.W.Z.; Butz, H.; Ding, Q.; Rotondo, F.; Evans, K.R.; Kupchak, P.; Dharsee, M.; Latif, A.; Pasic, M.D.; Lianidou, E.; et al. MiR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. *Mol. Ther.* **2015**, *23*, 1748–1758, doi:10.1038/mt.2015.129. 390–392
37. Krebs, M.; Solimando, A.G.; Kalogirou, C.; Marquardt, A.; Frank, T.; Sokolakis, I.; Hatzichristodoulou, G.; Kneitz, S.; Bargou, R.; Kübler, H.; et al. MiR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. *JCM* **2020**, *9*, 670, doi:10.3390/jcm9030670. 393–396
38. Salinas-Vera, Y.M.; Marchat, L.A.; Gallardo-Rincón, D.; Ruiz-García, E.; Astudillo-De La Vega, H.; Echavarría-Zepeda, R.; López-Camarillo, C. AngiomiRs: MicroRNAs Driving Angiogenesis in Cancer (Review). *Int J Mol Med* **2019**, *43*, 657–670, doi:10.3892/ijmm.2018.4003. 397–399
39. Wang, S.; Olson, E.N. AngiomiRs—Key Regulators of Angiogenesis. *Current Opinion in Genetics & Development* **2009**, *19*, 205–211, doi:10.1016/j.gde.2009.04.002. 400–401
40. Marquardt, A.; Solimando, A.G.; Kerscher, A.; Bittrich, M.; Kalogirou, C.; Kübler, H.; Rosenwald, A.; Bargou, R.; Kollmannsberger, P.; Schilling, B.; et al. Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. *Front. Oncol.* **2021**, *11*, 621278, doi:10.3389/fonc.2021.621278. 402–405